Registry Study of Immune-Related Adverse Events using ePRO in Cancer Patients Receiving Immune Checkpoint Inhibitors

Registry Study of Immune-Related Adverse Events using ePRO in Cancer Patients Receiving Immune Checkpoint Inhibitors - RESPECT study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046418

Enrollment

260

Registered

2021-12-20

Start date

2021-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer,Malignant pleural mesothelioma,Gastrointestinal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.diagnosed with lung cancer, malignant pleural mesothelioma, gastrointestinal cancer 2.patients scheduled to be treated with immune checkpoint inhibitors 3.20 years or older 4.Eastern Cooperative Oncology Group performance status of 0 -3 5.patients who can give written consent to participate in the study.

Exclusion criteria

Exclusion criteria: 1.does not have a device that can be used with ePRO 2.severe psychiatric disorder 3.cognitive impairment that may affect the completion of the questionnaire 4.native language is not Japanese

Design outcomes

Primary

Measure	Time frame
The purpose of this study is to obtain a database for descriptive studies on the actual status of immune-related adverse events, focusing on symptom-related adverse events, in cancer patients treated with regimens including immune checkpoint inhibitors.	—

Countries

Japan

Contacts

Public Contactkanako azuma

Tokyo Medical University Hospital Department of Pharmacy

azuma-k@tokyo-med.ac.jp03-3342-6111

Outcome results